October 2012

Recommendations help cardiologists navigate HF device options ()
Novel drug plus statin may trim LDL levels ()
Physicians engage more with EHR prompts when feedback, incentives added ()
EU approves Boston Sci's stent with different polymer ()
ECG results in AF patients predict adverse outcomes ()
Fiscal incentives may flop if docs perceive roadblocks ()
TCT: Mesh-covered stent shows promise for complete ST-segment resolution ()
St. Jude posts Q3 losses ()
Radial access benefits STEMI but not other ACS patients ()
TCT: Clopidogrel hypo-responsiveness predictive of complications but not death ()
TCT: Drug-eluting balloons best therapy for DES restenosis ()
TCT: Hospitalization costs for TAVR total $51K, finds German study ()
TCT: Abciximab can be safely delivered to STEMI patients through IV or directly to heart ()
TCT: Net margins for AVR vary as much as $33K across regions ()
Boehringer to shell out $95M to settle whistleblower case ()
TCT: No additional risk of bleeding with DES use in octogenarians ()
TCT: Smooth operators: High-volume = good outcomes for radial STEMI ()
Pediatric oxygenation system cleared for use in U.S. ()
TCT: Personalized hydration strategies significantly reduce contrast-induced nephropathy ()
Drug therapy vs. ablation in AF: It’s a dead heat ()
TCT: Newer DES effective in treating unprotected left main artery disease ()
TCT: When a negative outcome gets positive spin: Lessons from PC trial ()
TCT: Despite missing endpoint, docs tout PFO closure as patient-specific choice ()
Lists show clients shipped potentially tainted medications ()
TCT: After angio confirms ACS, should more potent antiplatelets be considered? ()
TCT: Benefits of shushing kidney-heart crosstalk hold over time ()
TCT: Questions remain on cost-effectiveness of FFR ()
TCT: TAVR's benefit persists at three years ()
TCT: Improving clinical skills key to interventionalists' success ()
TCT: Young physicians advised to develop leadership skills ()
TCT: 1-year results favorable for 38 mm stent ()
TCT: Goals of U.S. healthcare from 1927 will be the same in 2022 ()
TCT: PCI risk score may help curb costs, readmissions ()
TCT: Platelet reactivity monitoring bests standard prasugrel Rx for bleeds, thrombotic events ()
TCT: IVUS falls short for lesion measurement; stick to FFR ()
Going ‘lean’ helps hospital speed up stroke treatment ()
TCT: Discontinuation of DAPT at one week holds the most risk ()
TCT: FDA lays out improvement strategies for device innovation ()
EU panel gives nod to Xarelto for PE ()
EU warns of CV safety risk with diclofenac ()
NIH pulls plug on intervention for type 2 diabetes ()
FDA approves Sapien for high-risk TAVR patients ()
Younger men make up greater share of CHF admissions ()
Heart societies offer framework for physician pay ()
Making headway, maybe ()
PCI still performed at low-volume facilities with no back-up ()
Stryker buys Israeli brain stent maker for $135M ()
Pharmacist program targets HF, MI readmissions ()
Theravance and Merck ink hypertension, heart failure deal ()
AngioDynamics buys Vortex for $15M ()
Nixing copays on generic statins could save billions ()
Out with the bad: Lipid levels declining in U.S. ()
FDA: Tainted drugs may infect heart surgery patients ()
Underutilization of PCI is as much a problem as overutilization ()
TCT’s late-breakers cover gamut in interventional care ()
Parrillo leaves Cooper Heart for Hackensack chair ()
Preoperative tip for cardiac surgeons: Ask about falls ()
Lowering drug copays is cost neutral but still beneficial ()
Valve-in-valve may be OK for "no option" patients ()
FDA clears way for thoracic stent-graft ()
HRT may offer CV benefits in younger women ()
Edwards buys Dutch hemodynamic monitoring firm for $42M ()
Accuracy and public reporting ()
Bos Sci buys EP ablation firm for $90M ()
PCI use drops in states with public reporting ()
Methods sway hospital performance rankings ()
Stroke incidence increases among young adults ()
Diabetes screening in U.K. leads to no reduction in deaths ()
St. Jude launches 3D nav system for vascular, cardiac anatomy ()
State deregulation may decrease cost of CABG ()
Struggling with warfarin? Try relying on algorithm ()
New Volcano IVUS catheter nets clearance in U.S., EU ()
Business of healthcare will demand providers treat patients as customers ()
AdvaMed: Dashboard compares docs' outcomes performance, revenue generation ()
BMS forks over most Plavix, Avapro rights plus $80M to Sanofi ()
AdvaMed: Why and how healthcare reform will stick this time ()
Temporary break in DAPT may not increase ischemic risk ()
FDA green-lights subcutaneous ICD ()
Home-based HF program costs one-third less than clinic-based ()
GAO: FDA process overlooks information security risks for ICDs ()
Apixaban’s benefit preserved across risk categories ()
Left main disease patients fare better with Xience than Taxus ()
ICD patients need more education, psychological support ()
Mayo, Sutter General, Banner Heart ranked top CV hospitals ()
Blanket benefit of beta-blockers put in doubt ()
Oops: CMS revises HF, acute MI readmissions penalties ()
Medicure to file supplemental NDA for high-dose bolus of Aggrastat ()
FDA clears Bolton's stent graft system for TAAs ()
Obese patients should have MPI using conventional SPECT camera ()